Neurogene (NGNE) Cash from Financing Activities (2013 - 2026)

Neurogene has reported Cash from Financing Activities for 14 years, with the latest figure at $195000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 4775.0% year-over-year to $195000.0; the trailing twelve-month figure through Mar 2026 stood at $30.6 million (down 83.94% YoY), and the FY2025 full-year result was $30.4 million, down 83.47% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $195000.0, down from $20.7 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $190.1 million in Q4 2024, with the low at -$6.5 million in Q1 2024.
• Historically, Cash from Financing Activities has averaged $22.0 million across 5 years, with a median of $131000.0 in 2024.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 61944.86% — and 2024, when it plunged 6197.2%.
• Neurogene's Cash from Financing Activities stood at $66.4 million in 2022, then soared by 42.04% to $94.3 million in 2023, then soared by 101.56% to $190.1 million in 2024, then sank by 89.13% to $20.7 million in 2025, then tumbled by 99.06% to $195000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $195000.0 (Q1 2026), $20.7 million (Q4 2025), and $9.7 million (Q3 2025), per Business Quant data.